Treatment of tuberculosis in children

Expert Review of Anti-Infective Therapy

Volumn 6, Issue 6, 2008, Pages 939-957

  Cruz, Andrea T ^a   Starke, Jeffrey R ^b  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Drug resistance; Ethambutol; Isoniazid; Pediatric; Pyrazinamide; Rifampin; Tuberculosis

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; CAPREOMYCIN; CARBAMAZEPINE; CIPROFLOXACIN; CORTICOSTEROID; CYCLOSERINE; CYCLOSPORIN A; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; NAFCILLIN; NEVIRAPINE; ORAL CONTRACEPTIVE AGENT; PHENYTOIN; PREDNISONE; PROTEINASE INHIBITOR; PYRAZINAMIDE; PYRIDOXINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMATE; RIFAMPICIN; RIFATER; RNA DIRECTED DNA POLYMERASE INHIBITOR; STREPTOMYCIN; TACROLIMUS; UNINDEXED DRUG; WARFARIN; TUBERCULOSTATIC AGENT;

ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBACTERIAL ACTIVITY; ARTHROPATHY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BREAST FEEDING; CENTRAL NERVOUS SYSTEM DISEASE; CHEMOPROPHYLAXIS; COLOR BLINDNESS; COMBINATION CHEMOTHERAPY; COMORBIDITY; CREATININE CLEARANCE; DIRECTLY OBSERVED THERAPY; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; ENVIRONMENTAL EXPOSURE; EYE TOXICITY; GASTROINTESTINAL SYMPTOM; GOUT; HEMOLYSIS; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERSENSITIVITY REACTION; HYPOTHYROIDISM; IMMUNOMODULATION; INTRACRANIAL PRESSURE; LIVER TOXICITY; LOW DRUG DOSE; MEASLES LIKE RASH; MENINGITIS; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NEPHROTOXICITY; NEUROPATHY; OPTIC NEURITIS; OTOTOXICITY; PERICARDITIS; PERIPHERAL NEUROPATHY; PREGNANCY; PRURITUS; PSEUDOMEMBRANOUS COLITIS; PSYCHOSIS; QT PROLONGATION; REVIEW; SEIZURE; SIDE EFFECT; THROMBOCYTOPENIA; TUBERCULOMA; TUBERCULOSIS; TUBERCULOUS MENINGITIS; URIC ACID BLOOD LEVEL; ADJUVANT CHEMOTHERAPY; ADOLESCENT; CHILD; FEMALE; INFANT; MULTIDRUG RESISTANCE; MULTIMODALITY CANCER THERAPY; NEWBORN; PRESCHOOL CHILD; RISK FACTOR;

ADOLESCENT; ANTITUBERCULAR AGENTS; BREAST FEEDING; CHEMOTHERAPY, ADJUVANT; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; PREGNANCY; RISK FACTORS; TUBERCULOSIS;

EID: 59449109456     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.6.6.939     Document Type: Review

References (120)

1. Dye C. Global epidemiology of tuberculosis. Lancet 367, 938-940 (2006).
2. Wu P, Cowling BJ, Schooling CM et al. Age-period cohort analysis of tuberculosis notifications in Hong Kong from 1961 to 2005. Thorax 63, 312-316 (2008).
3. American Thoracic Society; CDC; Infectious Diseases Society of America. Treatment of tuberculosis. MMWR Recomm. Rep. 52, RR-11 (2003).
4. Graham SM, Gie RP, Schaaf HS, Coulter JBS, Espinal MA, Beyers N. Childhood tuberculosis: clinical research needs. Int. J. Tuberc. Lung Dis. 8, 648-657 (2004).
5. Starke JR. New concepts in childhood tuberculosis. Curr. Opin. Pediatr. 19, 306-313 (2007).
6. American Academy of Pediatrics. Tuberculosis. In: Red Book Report of the Committee on Infectious Diseases (26th Edition), Pickering LJ (Ed.). American Academy of Pediatrics, IL, USA 678-698 (2006).
7. World Health Organization. Guidance for national tuberculosis programmes on the management of tuberculosis in children. World Health Organization, Geneva, Switzerland (2006).
8. Donald PR, Gent WL, Seifart HI, Lamprecht JH, Parkin DP. Cerebrospinal fluid isoniazid concentrations in children with tuberculous meningitis: the influence of dosage and acetylation status. Pediatrics 89, 247-250 (1992).
9. El Sahly HM, Teeter LD, Pawlak RR, Musser JM, Graviss EA. Drug-resistant tuberculosis: a disease of target populations in Houston, Texas. J. Infect. 53, 5-11 (2006).
10. Aziz MA, Wright A, Laszlo A et al. Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis. Lancet 368, 2142-2154 (2006).
11. Patsolos PN, Perucca E. Clinically important interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol. 2, 473-481 (2003).
12. Gilroy SA, Rogers MA, Blair DC. Treatment of latent tuberculosis infection in patients aged ≥35 years. Clin. Infect. Dis. 31, 826-829 (2000).
13. Standal BK, Kao-Chen SM, Yang GY et al. Early changes in pyridoxine status of patients receiving isoniazid therapy. Am. J. Clin. Nutr. 27, 479-484 (1974)
14. American Thoracic Society. Targeted tuberculin. testing and treatment of latent tuberculosis infection. Am. J. Respir. Crit. Care Med. 161, 1376-1395 (2000).
15. Wu SS, Chao CS, Vargas JH et al. Isoniazid-related hepatic failure in children: a survey of liver transplantation centers. Transplantation 84, 173-179 (2007).
16. Saukkonen JJ, Cohn DL, Jasmer RM et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am. J. Respir. Crit. Care Med. 174, 935-952 (2006).
17. Mahajan M, Rohatgi D, Talwar V, Patni SK, Mahajan P, Agarwal DS. Serum and cerebrospinal fluid concentrations of rifampicin at two dose levels in children with tuberculous meningitis. J. Commun. Dis. 29, 269-274 (1997).
18. Ellard GA, Humphries MJ, Allen BW. Cerebrospinal fluid concentrations and the treatment of tuberculous meningitis. Am. Rev. Resp. Dis. 148, 650-655 (1993).
19. Nijland HM, Ruslami R, Suroto AJ et al. Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis. Clin. Infect. Dis. 45, 1001-1007 (2007).
20. Burman WJ, Gallicano K, Peloquin C. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin. Pharmacokinet. 40, 327-341 (2001).
21. Chintu C, Mwaba P. Tuberculosis infection in children with human immunodeficiency virus infection. Int. J. Tuberc. Lung Dis. 9, 477-484 (2005).
22. Blake MJ, Abdel-Rahman SM, Jacobs RF, Lowery NK, Sterling TR, Kearns GL. Pharmacokinetics of rifapentine in children. Pediatr. Infect. Dis. J. 25, 405-409 (2006).
23. Munsiff SS, Kambili C, Ahuja SD. Rifapentine for the treatment of pulmonary tuberculosis. Clin. Infect. Dis. 43, 1468-1475 (2006).
24. Singh P, Mishra AK, Malonia SK et al. The paradox of pyrazinamide: an update on the molecular mechanisms of pyrazinamide resistance in mycobacteria. J. Commun. Dis. 38, 288-298 (2006).
25. Donald PR, Seifart H. Cerebrospinal fluid pyrazinamide concentrations in children with tuberculous meningitis. Pediatr. Infect. Dis. J. 7, 469-471 (1988).
26. Nishimura Y, Kurata N, Sakurai E, Yasuhara H. Inhibitory effect of antituberculosis drugs on human cytochrome P450-mediated activities. J. Pharmacol. Sci. 96, 293-300 (2004).
27. Graham SM, Bell DJ, Nyirongo S et al. Low levels of pyrazinamide and ethambutol in children with tuberculosis and impact of age, nutritional status, and human immunodeficiency virus infection. Antimicrob. Agents Chemother. 50, 407-413 (2006).
28. Hannan MM, Desmond EP, Morlock GP, Mazurek GH, Crawford JT. Pyrazinamide-monoresistant Mycobacterium tuberculosis in the United States. J. Clin. Microbiol. 39, 647-650 (2001).
29. Hesseling AC, Rabie H, Marais BJ et al. Bacille Calmette - Guerin vaccine-induced disease in HIV-infected and HlV-uninfected children. Clin. Infect. Dis. 42, 548-558 (2006).
30. Bobrowitz ID. Ethambutol in tuberculous meningitis. Chest 7, 629-632 (1972).
31. Donald PR, Maher D, Maritz JS et al. Ethambutol dosage for the treatment of children: literature review and recommendations. Int. J. Tuberc. Lung Dis. 10, 1318-1330 (2006).
32. World Health Organization. Ethambutol efficacy and toxicity: literature review and recommendations for daily and intermittent dosage in children. WHO/HTM/TB/2006.365. Geneva, Switzerland (2006).
33. Centers for Disease Control and Prevention. Extensively drug-resistant tuberculosis - United States, 1993-2006 MMWR Morb. Mortal. Wkly. Rep. 56, 250-253 (2007).
34. Centers for Disease Control and Prevention. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs - worldwide, 2000-2004. MMWR Morb. Mortal. Wkly. Rep. 55, 301-305 (2006).
35. Donald PR, Sirgel FA, Venter A et al. Early bactericidal activity of antituberculosis agents. Expert Rev. Anti-Infect. Ther. 1, 141-155 (2003).
36. Gaillard JL, Silly C, Le Masne A et al. Cerebrospinal fluid penetration of amikacin in children with community-acquired bacterial meningitis. Antimicrob. Agents Chemother. 39, 253-255 (1995).
37. Contopoulos-Ioannidis DG, Giotis ND, Baliatsa DV, Ioannidis JP. Extended interval aminoglycoside administration for children: a meta-analysis. Pediatrics 114, E111-E118 (2004).
38. Chen Y, Huang WG, Zha DJ et al. Aspirin attenuates gentamicin ototoxicity: from the laboratory to the clinic. Hear. Res. 226, 178-182 (2007).
39. Sha SH, Qiu JH, Schacht J. Aspirin to prevent gentamicin-induced hearing loss. N. Engl. J. Med. 354, 1856-1857 (2006).
40. Martínez-Salgado C, López-Hernández FJ, López-Novoa JM. Glomerular nephrotoxicity of aminoglycosides. Toxicol. Appl. Pharmacol. 223, 86-98 (2007).
41. Maus CE, Plikaytis BB, Shinnick TM. Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 49, 3192-3197 (2005).
42. Krüüner A, Jureen P, Levina K, Ghebremichael S, Hoffner S. Discordant resistance to kanamycin and amikacin in drug-resistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 47, 2971-2973 (2003).
43. Donald PR, Seifart HI. Cerebrospinal fluid concentrations of ethionamide in children with tuberculous meningitis. J. Pediatr. 115, 483-486 (1989).
44. McDonnell ME, Braverman LE, Bernardo J. Hypothyroidism due to ethionamide. N. Engl. J. Med. 352, 2757-2759 (2005).
45. Wang F, Langley R, Gulten G et al. Mechanism of thioamide drug action against tuberculosis and leprosy. J. Exp. Med. 204, 73-78 (2007).
46. DeBarber AE, Mdluli K, Bosman M, Bekker LG, Barry CE 3rd. Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis. Proc. Natl Acad. Sci. USA 97, 9677-9682 (2000).
47. Balabanova Y, Ruddy M, Hubb J et al. Multidrug-resistant tuberculosis in Russia: clinical characteristics, analysis of second-line drug resistance, and development of standardized therapy. Eur. J. Clin. Microbiol. Infect. Dis. 24, 136-139 (2005).
48. Moadebi S, Harder CK, Fitzgerald MJ, Elwood KR, Marra F. Fluroquinolones for the treatment of pulmonary tuberculosis. Drugs 67, 2077-2099 (2007).
49. Berning SE, Cherry TA, Iseman MD. Novel treatment of meningitis caused by multidrug-resistant Mycobacterium tuberculosis with intrathecal levofloxacin and amikacin: case report. Clin. Infect. Dis. 32, 643-646 (2001).
50. Ginsburg AS, Grosset JH, Bishai WR. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect. Dis. 3, 432-442 (2003).
51. Shandil RK, Jayaram R, Kaur P et al. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob. Agents Chemother. 51, 576-582 (2007).
52. Dooley KE, Golub J, Goes FS, Merz WG, Sterling TR. Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis. Clin. Infect. Dis. 34, 1607-1612 (2002).
53. Wang JY, Hsueh PR, Jan IS et al. Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas. Thorax 61, 903-908 (2006).
54. Ginsburg AS, Hooper N, Parrish N et al. Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin. Infect. Dis. 37, 1448-1452 (2003).
55. Bozeman L, Burman W, Metchock B et al. Fluoroquinolone susceptibility among Mycobacterium tuberculosis isolates from the United States and Canada. Clin. Infect. Dis. 40, 386-391 (2005).
56. Peloquin CA, Zhu M, Adam RD, Singleton MD, Nix DE. Pharmacokinetics of para-aminosalicylic acid granules under four dosing conditions. Ann. Pharmacother. 35. 1332-1338 (2001).
57. DeVincenzo JP, Berning SE, Peloquin CA, Husson RN. Multidrug-resistant tuberculosis meningitis: clinical problems and concentrations of second-line antituberculous medications. Ann. Pharmacother. 33, 1184-1188 (1999).
58. Vega P, Sweetland A, Acha J et al. Psychiatric issues in the management of patients with multidrug-resistant tuberculosis. Int. J. Tuberc. Lung Dis. 8, 749-759 (2004).
59. Shin S, Guerra D, Rich M et al. Treatment of multidrug-resistant tuberculosis during pregnancy: a report of 7 cases. Clin. Infect. Dis. 36, 996-1003 (2003).
60. Zar HJ, Cotton MF, Straus S et al. Effect of isoniazid prophylaxis on mortality and the incidence of tuberculosis in children with HIV: randomized controlled trial. BMJ 334, 136-142 (2006).
61. Ijaz K, Jereb JA, Lambert LA et al. Severe or fatal liver injury in 50 patients in the United States taking rifampin and pyrazinamide for latent tuberculosis infection. Clin. Infect. Dis. 42, 346-355 (2006).
62. Ena J, Valls V. Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid for latent tuberculosis infection: a meta-analysis. Clin. Infect. Dis. 40, 670-676 (2005).
63. Reichman LB, Lardizabal A, Hayden CH. Considering the role of four months of rifampin in the treatment of latent tuberculosis infection. Am. J. Resp. Crit. Care Med. 170, 832-835 (2004).
64. Sneag DB, Schaaf HS, Cotton MF, Zar HJ. Failure of chemoprophylaxis with standard antituberculosis agents in child contacts of multidrug-resistant tuberculosis cases. Pediatr. Infect. Dis. J. 26, 1142-1146 (2007).
65. Schaaf HS, Victor TC, Engelke E et al. Minimal inhibitor concentration of isoniazid in isoniazid-resistant Mycobacterium tuberculosis isolates from children. Eur. J. Clin. Microbiol. Infect. Dis. 26, 203-205 (2007).
66. Katiyar SK, Bihari S, Prakash S et al. A randomized controlled trial of high-dose isoniazid adjunctive therapy for multidrug-resistant tuberculosis. Int. J. Tuberc. Lung Dis. 12, 139-145 (2008).
67. Gandhi NR, Moll A, Sturm AW et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368, 1575-1580 (2006).
68. Perlman DC, Segal Y, Rosenkranz S et al. The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosis. Clin. Infect. Dis. 41, 1638-1647 (2005).
69. Gurumurthy P, Ramachandran G, Hemanth-Kumar AK et al. Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease. Antimicrob. Agents Chemother. 48, 4473-4475 (2004).
70. McIlleron H, Meintjes G, Burman WJ, Maartens G. Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. J. Infect. Dis. 196, S63-S75 (2007).
71. Wells CD, Cegielski JP, Nelson LJ et al. HIV infection and multidrug-resistant tuberculosis - the perfect storm. J. Infect. Dis. 196, S86-S107 (2007).
72. Centers for Disease Control & Prevention. Acquired rifamycins resistance in persons with advanced HIV disease being treated for active tuberculosis with intermittent rifamycin-based regimens. MMWR Morb. Mortal. Wkly. Rep. 51, 214-215 (2002).
73. Tunkel AR, Hartman BJ, Kaplan SL et al. Practice guidelines for the management of bacterial meningitis. Clin. Infect. Dis. 39, 1267-1284 (2004).
74. Mayosi BM, Burgess LJ, Doubell AF. Tuberculous pericarditis. Circulation 112, 3608-3616 (2005).
75. Rikimaru T. Endobronchial tuberculosis. Expert Rev. Anti Infect. Ther. 2, 245-251 (2004).
76. Alrajhi AA, Halim MA, al-Hokail A, Alrabiah F, al-Omran K. Corticosteroid treatment of peritoneal tuberculosis. Clin. Infect. Dis. 27, 52-56 (1998).
77. Wiysonge CS, Ntsekhe M, Gumedze F et al. Contemporary use of adjunctive corticosteroids in tuberculous pericarditis. Int. J. Cardiol. 124(3), 388-390 (2007).
78. Elliott AM, Luzze H, Quigley MA et al. A randomized, double-blind, placebo-controlled trial of the use of prednisolone as an adjunct to treatment in HIV-1 associated pleural tuberculosis. J. Infect. Dis. 190, 869-878 (2004).
79. Caminero JA. Treatment of multidrug-resistant tuberculosis: evidence and controversies. Int. J. Tuberc. Lung Dis. 10, 829-837 (2006).
80. Lalloo UG, Naidoo R, Ambaram A. Recent advances in the medical and surgical treatment of multi-drug resistant tuberculosis. Curr. Opin. Pulm. Med. 12, 179-185 (2006).
81. Jouveshomme S, Dautzenberg B, Bakdach H, Derenne JP. Preliminary result of collapse therapy with plombage for pulmonary disease caused by multidrug-resistant mycobacteria. Am. J. Resp. Crit. Care Med. 157, 1609-1615 (1998).
82. Goussard P, Gie R. Airway involvement in pulmonary tuberculosis. Paed. Resp. Rev. 8, 118-123 (2007).
83. Norrby SR, Nord CE, Finch R. Lack of development of new antimicrobial drugs: a potential serious threat to public health. Lancet Infect. Dis. 5, 115-119 (2005).
84. Spigelman MK. New tuberculosis therapeutics: a growing pipeline. J. Infect. Dis. 196, S28-S34 (2007).
85. Rustomjee R, Diacon AH, Allen J et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in pulmonary tuberculosis. Antimicrob. Agents Chemother. 52(8), 2831-2835 (2008).
86. Von der Lippe B, Sandven P, Brubakk O. Efficacy and safety of linezolid in multidrug-resistant tuberculosis - a report of 10 cases. J. Infect. 52, 92-96 (2006).
87. Tato M, de la Pedrosa EG, Cantón R et al. In vitro activity of linezolid against Mycobacterium tuberculosis complex, including multidrug-resistant Mycobacterium bovis isolates. Int. J. Antimicrob. Agents 28, 75-78 (2006).
88. Murray MF. Nicotinamide: an oral antimicrobial agent with activity against both Mycobacterium tuberculosis and human immunodeficiency virus. Clin. Infect. Dis. 36, 453-460 (2003).
89. Okwera A, Whalen C, Byekwaso F et al. Randomised trial of thiacetazone and rifampicin-containing regimens for pulmonary tuberculosis in HIV-infected Ugandans. Lancet 344, 1323-1328 (1994).
90. Lawn SD, Griffin GE. Further consequences of thioacetazone-induced cutaneous reactions. Int. J. Tuberc. Lung Dis. 4, 92-93 (2000).
91. Prabhakaran K, Harris EB, Randhawa B, Adams LB, Williams DL, Hastings RC. Use of β-lactam/β-lactamase inhibitor combinations as antimycobacterial agents. Microbios 76, 251-261 (1993).
92. Casal MJ, Rodriguez FC, Luna MD, Benavente MC. In vitro susceptibility of Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis, Mycobacterium avium, Mycobacterium fortuitum, and Mycobacterium chelonae to ticarcillin in combination with clavulanic acid. Antimicrob. Agents Chemother. 31, 132-133 (1987).
93. Nadler JP, Berger J, Nord JA. Amoxicillin-clavulanic acid for treating drug-resistant Mycobacterium tuberculosis. Chest 99, 1025-1026 (1991).
94. Falzari K, Zhu Z, Pan D, Lui H, Hongmanee P, Franzblau SG. In vitro and in vivo activities of macrolide derivatives against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 49, 1447-1454 (2005).
95. Sacks LV, Pendle S, Orlovic D et al. Adjunctive salvage therapy with inhaled aminoglycosides for patients with persistent smear-positive pulmonary tuberculosis. Clin. Infect. Dis. 32, 44-49 (2001).
96. Sherry E, Reynolds M, Sivananthan S, Mainawalala S, Warnke PH. Inhalational phytochemicals as possible treatment for pulmonary tuberculosis: two case reports. Am. J. Infect. Control 32, 369-376 (2004).
97. Qu Toit LC, Pillay V, Danckwerts MP. Tuberculosis chemotherapy: current drug delivery approaches. Resp. Res. 7, 118-136 (2006).
98. Debnath PR, Tripathi R, Kandpall D, Kumar B, Malik E, Sharma SB. Isolated tubercular liver abscess in children treated with percutaneous isoniazid infusion. Indian J. Tuberc. 54, 149-151 (2007).
99. Spyridis NP, Spyridis PG, Gelesme A et al. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Clin. Infect. Dis. 45, 715-722 (2007).
100. Page KR, Sifakis F, Montes de Oca R et al. Improved adherence and less toxicity with rifampin vs. isoniazid for treatment of latent tuberculosis. Arch. Intern. Med. 166, 1863-1870 (2006).
101. Lardizabal A, Passannante M, Kojakali F, Hayden C, Reichman LB. Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin. Chest 130, 1712-1717 (2006).
102. Frieden TR, Sterling T, Pablos-Mendez A et al. The emergence of drug-resistant tuberculosis in New York City. N. Engl. J. Med. 328, 521-526 (1993).
103. Frieden TR, Sherman LF, Maw KL et al. A multi-institutional outbreak of highly drug-resistance tuberculosis: epidemiology and clinical outcomes. JAMA 276, 1229-1235 (1996).
104. Kong Y, Cave MD, Zhang L et al. Association between Mycobacterium tuberculosis Beijing/W lineage strain infection and extrathoracic tuberculosis: insights from epidemiologic and clinical characterization of the three principal genetic groups of M. tuberculosis clinical isolates. J. Clin. Microbiol 45, 409-414 (2007).
105. Kim H-R, Hwang SS, Kim HJ et al. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. Clin. Infect. Dis. 45, 1290-1295 (2007).
106. Shah NS, Wright A, Bai G-H et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg. Infect. Dis. 13, 380-387 (2007).
107. Munsiff SS, Li J, Cook SV et al. Trends in drug-resistant Mycobacterium tuberculosis in New York City, 1991-2003. Clin Infect. Dis. 42, 1711-1712 (2006).
108. Hamilton CD, Sterling TR, Blumberg HM et al. Extensively drug-resistant tuberculosis: are we learning from history or repeating it? Clin. Infect. Dis. 45, 338-342 (2007).
109. Drobac PC, Mukherjee JS, Joseph JK et al. Community-based therapy for children with multidrug-resistant tuberculosis. Pediatrics 117, 2022-2028 (2006).
110. Palme IB, Gudetta B, Bruchfeld J et al. Impact of human immunodeficiency virus 1 infection on clinical presentation, treatment outcome, and survival in a cohort of Ethiopian children with tuberculosis. Pediatr. Infect. Dis. J. 21, 1053-1061 (2002).
111. Puthanakit T, Oberdorfer P, Akarathum N et al. Immune reconstitution syndrome after highly active antiretroviral therapy in human immunodeficiency virus-infected Thai children. Pediatr. Infect. Dis. J. 25, 53-58 (2006).
112. Zampoli M, Kilborn T, Eley B. Tuberculosis during early antiretroviral-induced immune reconstitution in HIV-infected children. Int. J. Tuberc. Lung Dis. 11, 417-423 (2007).
113. Wallis RS. Reconsidering adjuvant immunotherapy for tuberculosis. Clin. Infect. Dis. 41, 201-208 (2005).
114. Reljic R. IFN-γ therapy of tuberculosis and related infections. J. Interferon Cytokine Res. 27, 253-263 (2007).
115. Condos R, Rom WN, Schluger NW. Treatment of multidrug-resistant pulmonary tuberculosis with interferon-γ via aerosol. Lancet 349, 1513-1515 (1997).
116. Johnson JL, Ssekasanvu E, Okwera A et al. Randomized trial of adjunctive interleukin-2 in adults with pulmonary tuberculosis. Am. J. Resp. Crit. Care Med. 168, 185-191 (2003).
117. Wallis RS, Kyambadde P, Johnson JL et al. A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. AIDS 18, 257-264 (2004).
118. Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N. Engl. J. Med. 345, 1098-1104 (2001).
119. Sichletidis L, Settas L, Spyratos D et al. Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis. Int. J. Tuberc. Lung Dis. 10, 1127-1132 (2006).
120. Mayanja-Kizza H, Jones-Lopez E, Okwera A et al. Immunoadjuvant prednisolone therapy for HIV-associated tuberculosis: a Phase 2 clinical trial in Uganda. J. Infect. Dis. 191, 856-865 (2005).